Impact of baseline characteristics and beta‐cell function on the efficacy and safety of subcutaneous once‐weekly semaglutide: A patient‐level, pooled analysis of the SUSTAIN 1‐5 trials
- DOI
- 10.1111/dom.13896
- Published
- 2019-11-14
- Container
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1111/dom.13896,
title = {Impact of baseline characteristics and beta‐cell function on the efficacy and safety of subcutaneous once‐weekly semaglutide: A patient‐level, pooled analysis of the SUSTAIN 1‐5 trials},
author = {Vanita R. Aroda and Matthew S. Capehorn and Louis Chaykin and Juan P. Frias and Nanna L. Lausvig and Stanislava Macura and Jörg Lüdemann and Sten Madsbad and Julio Rosenstock and Omur Tabak and Sayeh Tadayon and Stephen C. Bain},
year = {2019},
journal = {Diabetes, Obesity and Metabolism},
doi = {10.1111/dom.13896},
url = {https://doi.org/10.1111/dom.13896}
}RIS
TY - JOUR TI - Impact of baseline characteristics and beta‐cell function on the efficacy and safety of subcutaneous once‐weekly semaglutide: A patient‐level, pooled analysis of the SUSTAIN 1‐5 trials AU - Vanita R. Aroda AU - Matthew S. Capehorn AU - Louis Chaykin AU - Juan P. Frias AU - Nanna L. Lausvig AU - Stanislava Macura AU - Jörg Lüdemann AU - Sten Madsbad AU - Julio Rosenstock AU - Omur Tabak AU - Sayeh Tadayon AU - Stephen C. Bain PY - 2019 JO - Diabetes, Obesity and Metabolism DO - 10.1111/dom.13896 UR - https://doi.org/10.1111/dom.13896 ER -
APA
Aroda, V. R., Capehorn, M. S., Chaykin, L., Frias, J. P., Lausvig, N. L., Macura, S., Lüdemann, J., Madsbad, S., Rosenstock, J., Tabak, O., Tadayon, S., & Bain, S. C. (2019). Impact of baseline characteristics and beta‐cell function on the efficacy and safety of subcutaneous once‐weekly semaglutide: A patient‐level, pooled analysis of the SUSTAIN 1‐5 trials. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.13896
Source records
- crossref · retrieved 2026-09-24T23:23:47.511Z